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Abstract
Background: Some observational studies have found increased HIV risk associated with self-
reported use of injectable depot medroxyprogesterone acetate (DMPA). Testing blood samples for 
MPA, the progestin in DMPA, permits validation of self-reported data and exploration of whether 
potential HIV risk is correlated with MPA levels, which are highest soon after injection.
Methods: We conducted a case-control study testing archived serum from women who 
participated in three longitudinal studies of HIV prevention in East and southern Africa. Case 
samples, from women who acquired HIV, were from visits that occurred at or immediately prior to 
the first evidence of HIV infection. Secondary analyses restricted to case samples collected within 
15 and 30 days of the estimated date of HIV infection. Matched control samples were from 
women who remained HIV-uninfected. We used multivariable conditional logistic regression to 
compare exogenous hormone levels, quantified through mass spectrometry, among cases and 
controls.
Results: When restricted to cases with samples collected within ≤15 days of estimated date of 
HIV infection, MPA detection was more frequent among women who acquired HIV (adjusted 
odds ratio [AOR]=2.75, 95% confidence interval [CI] 1.22-6.19). In this subset, the increase in 
HIV risk was only among samples with MPA detected at a low level of 0.02-0.50ng/ml: 36.7% of 
cases and 9.4% of controls, AOR=6.03, 95% CI 2.50-14.54.
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Conclusions: Detection of MPA at low levels close to the estimated time of HIV acquisition was 
significantly more frequent among women who acquired HIV. Studies are needed that explore 
biological mechanisms elicited by any MPA level and HIV risk.
Keywords
hormonal contraception; DMPA; HIV; women; Africa
Introduction
The availability of safe and effective reversible contraception is a top priority in women’s 
health globally; greater contraceptive choice affords women greater control in planning their 
families and maintaining their health and the health of their children (1, 2). In many settings 
where the predominance of contracepting women use injectable hormonal methods, women 
also face a high risk of HIV, and a recent update to the World Health Organization (WHO) 
Medical Eligibility Criteria acknowledges the potential for injectable contraceptives to 
increase HIV risk (3-5). The data supporting this recommendation are from multiple 
observational analyses and meta-analyses, some, but not all, of which demonstrate increased 
HIV risk with the use of intramuscularly-administered depot medroxyprogesterone acetate 
(DMPA) (6-8). The risk estimates in these studies could be spuriously derived from 
inaccurate measurement of self-reported contraceptive use (9) and/or sexual behavior (10, 
11), or they could represent true behaviorally and/or biologically driven increases in HIV 
risk.
Biologic studies have generated many hypotheses about mechanisms by which DMPA, or its 
progestin, MPA that circulates as a measurable metabolite in blood, could enhance HIV 
susceptibility (12). Pharmacokinetic properties of DMPA include an early peak in serum 
with steep declines during the first 30 days and less steep declines during the subsequent 60 
days that enable maintenance of levels above thresholds needed for contraceptive efficacy 
(13). Notably, there is large inter-individual variation in peak MPA levels (14). One 
mechanistic hypothesis about the potential for DMPA to increase HIV susceptibility in 
women relates to the high amounts of MPA in serum immediately following administration 
and that this amount is sufficient to elicit inflammatory responses that increase HIV 
susceptibility (12, 15).
Given uncertainty in the accuracy of self-reported contraceptive data and hypotheses for 
HIV susceptibility related to hormonal quantities, particularly MPA levels, the objective of 
our study was to use state-of-the-art laboratory techniques to measure progestin levels in 
women’s serum and relate these levels to HIV seroconversion using a case-control study 
design. In a rapidly expanding field, this study is novel as it relates incident HIV infection 
with laboratory-defined measures of contraceptive exposure.
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Methods
Population.
Women were participating in three prospective HIV prevention studies that took place from 
2004-2013 in 7 African countries (South Africa, Rwanda, Zambia, Kenya, Uganda, 
Tanzania, and Botswana). All women were HIV-negative members of HIV serodiscordant 
couples. Their male partners living with HIV were ART naïve at enrollment, underwent 6-
monthly CD4+ T cell count and HIV RNA quantification during the studies, and were 
referred to ART as soon as they were eligible based on the national guidelines of the time.
The Partners in Prevention HSV/HIV Transmission Study (Clinicaltrials.gov # 
NCT00194519) was a placebo-controlled randomized trial to evaluate the efficacy of daily 
acyclovir for HIV prevention when used by people co-infected with HIV and HSV-2. The 
primary findings included that daily acyclovir had no effect on HIV transmission (16). The 
Couples Observational Study was a longitudinal cohort study to identify immune correlates 
of HIV infection (17). In this study, as well as the Partners in Prevention Study, women 
underwent quarterly HIV testing. In the Partners PrEP Study (Clinicaltrials.gov 
#NCT00557245), a placebo-controlled double-blind, randomized trial to evaluate daily, oral 
tenofovir-based pre-exposure prophylaxis (PrEP) for HIV prevention, women attended 
monthly study visits for HIV testing and study drug refills. The Partners PrEP Study 
demonstrated 75% efficacy overall and 66% efficacy among women for co-formulated 
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and 67% efficacy overall and 71% 
efficacy among women for single agent TDF (18). In all studies, quarterly interviewer-
administered questionnaires captured self-reported data on sexual behavior and 
contraceptive use. At enrollment and when clinically indicated, genital exams were 
conducted and endocervical swab samples were collected from women for screening for 
Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis with the 
GenProbe Aptima Combo2 nucleic acid amplification assay (San Diego, California). Blood 
samples were collected from women at quarterly visits and in the event of seroconversion 
and archived at −80°C.Contraception was promoted through family planning counseling at 
all sites but use of contraception was not a study requirement. Participants could access 
contraceptives at research sites or by referral.
Study design.
We conducted a case-control study with sampling based on HIV seroconversion status and 
defined hormone exposure using quantified levels of specified progestins for all cases and 
controls. Case samples were from all women who seroconverted in the trials and these were 
matched in a 1:4 ratio with control samples from women who did not acquire HIV. To 
identify women for the control group, we applied a validated risk scoring tool to each case 
participant and frequency matched controls to cases based on the risk score (19) and study 
arm (active or placebo, Figure 1). The risk score, which incorporates age, children within the 
partnership, occurrence of condomless sex, male circumcision status, and the HIV viral load 
of the partner living with HIV, all from the time of study enrollment, is a stronger predictor 
of HIV transmission than any of its individual factors or other common factors associated 
with HIV seroconversion. To avoid over-matching, we limited matching to these two factors 
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(risk score and study arm) and considered other potential confounders for inclusion in our 
final models.
Up to 2 samples per woman were analyzed – a sample from the visit with the first evidence 
of HIV infection (i.e., sometimes after the estimated date of HIV acquisition) and the visit 
immediately prior to the first evidence of HIV infection. For controls, up to 2 samples from 
sequential visits that occurred at the same time of HIV detection in the cases were selected 
for testing to ensure that case and control samples were collected after approximately the 
same duration of study follow up. Control samples were excluded from selection if the HIV-
infected male partner had already initiated ART to reflect the lack of seroconversion in these 
studies when partners were using ART with suppressed viremia (18, 20).
HIV outcome.
HIV seroconversions were defined by rapid HIV antibody tests conducted at study sites at 
each study visit and positive results were confirmed by plasma HIV RNA quantification. 
Stored samples from seroconverters that were collected at enrollment into the parent study 
were tested for HIV RNA. If RNA was not detected in the enrollment sample, women were 
determined to have incident HIV infection and included as cases. If HIV RNA was detected 
at enrollment, women were classified as HIV-infected at enrollment and excluded from this 
study. For all incident infections, archived samples from study visits immediately prior to 
seroconversion were tested retrospectively for HIV RNA to determine whether the first 
evidence of infection was the same day as when the woman tested positive at the study site 
or at an earlier time point. The date of first evidence of infection was determined to be the 
earliest date when HIV RNA was detected (which could be as late as the day when rapid 
HIV antibody tests were first positive or at an earlier time point). If the first quantifiable HIV 
RNA occurred on the same day as the first antibody positivity, we estimated the date of HIV 
infection to be the midpoint between the day of the last antibody negative test and the day 
when serology and RNA were first positive. If the first evidence of infection (e.g. date 
sample drawn with quantifiable HIV RNA) was at a visit prior to the first antibody positive 
date, we estimated the date of infection to have been 17 days prior to the date of first RNA 
positive test result (21, 22).
Measurement of exogenous hormones.
A validated, high-performance liquid chromatography-heated electrospray ionization-
tandem triple quadrupole mass spectrometry (LC-MS/MS) assay was used to simultaneously 
quantify the amount of four progestins in each sample (23, 24). Progestins included MPA 
and levonorgestrel (LNG), used in oral contraceptives and implants; norethindrone (NET), 
used in another injectable known as NET-EN; and etonogestrel (ENG), used in a 
contraceptive implant. Additionally, exogenous ethynyl estradiol (EE2) and endogenous 
progesterone (P4) and estradiol (E2) were measured in the same assay.
Statistical analysis.
We used conditional logistic regression to determine the association of each exogenous 
hormone with case-control status. In our primary analysis, we used the exogenous hormone 
levels from case and control samples collected: 1) at the visit with the first evidence of HIV 
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infection (or equivalent for controls) and 2) the visit immediately prior to the first evidence 
of infection. To reduce the amount of time elapsing between the estimated date of infection 
and sample collection, we conducted secondary analyses where we restricted the cases to 
those with samples collected 1) ≤30 days and 2) ≤15 days before or after the estimated 
infection date. In these secondary analyses, case samples were compared to control samples 
collected at the visit comparable to the case visit that occurred immediately prior to the first 
evidence of infection.
Samples with quantities less than the lower limit of quantification (LLQ) were assigned a 
value equal to half the LLQ for that particular analyte (LLQ=0.02 ng/mL for LNG, ENG, 
and MPA; 0.04 ng/mL for NET; 0.01 for E2). For MPA, serum levels were categorized based 
on quartiles and our understanding of MPA pharmacokinetics (25). Other analytes could 
only be dichotomized into detected/undetected due to the infrequency of detection. All 
models included variables to account for the HIV risk score and study arm, which were 
matching variables. Variables for the woman’s age and whether the woman reported any 
condomless sex during the past month were included in all final models based on a priori 
knowledge of the role for these factors to confound the contraception-HIV relationship. For 
MPA analyses, other potential confounders such as infection with a curable STI and 
partner’s HIV viral load, were included in models if they contributed to a substantial (>10%) 
change in the point estimate. Finally, we adjusted the MPA models for E2 levels to 
determine whether hypoestrogenism, characterized by low levels of E2, may account for any 
association (26, 27). SAS 9.4 (SAS Institute, Cary, NC, USA) was used for all statistical 
analyses.
Ethics.
Protocols for all three prospective studies were approved by the Human Subjects Division at 
the University of Washington and research ethics committees overseeing each study site. 
Women provided written informed consent, which included archiving of blood samples for 
future testing related to HIV.
Results
Participant characteristics.
132 HIV-seroconverting women with available samples (cases) were matched to 525 non-
seroconverting women (controls, Figure 1). Of these women, 115 cases had samples 
available from the visit with the first evidence of infection and 525 controls had sample from 
the time point comparable to the case time point. 117 cases had samples available at the visit 
immediately prior to the first evidence of HIV infection and 414 controls had samples from 
the comparable time point. Baseline characteristics were similar between women with 
samples available at both time points or only one time point (data not shown). The median 
age for cases was 27 years (interquartile range [IQR] 24-33) and for controls, the median 
age was 30 years (IQR 24-37, Table 1). Most women were married to their HIV-infected 
study partner and had at least one child. Women reported a median of 3 sex acts with their 
partner in the month prior to study enrolment (IQR 1-4 for cases and 2-6 for controls) and 
17.1% of cases and 13.4% of controls were infected with a curable STI at enrollment.
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Of the 115 samples available from cases at the study visit with first evidence of HIV 
infection, the median time between sample collection and estimated date of HIV infection 
was 17 days (IQR=15-46 days, Table 1). Using the set of case samples drawn at the visit 
prior to the first evidence of infection, which incorporates samples drawn before and after 
the estimated date of infection, the median time between sample collection and estimated 
date of HIV infection was 45 days prior to estimated date of infection (IQR=29-67 days 
before, 103/117 [88.0%] of samples were before infection). Restricting to samples collected 
within 30 days of the estimated date of HIV infection resulted in a set of 81 cases collected 
at a median of 17 days after infection (IQR 14-17 days after infection, 64/81 [79.0%] were 
after infection). Restricting further to samples collected within 15 days of the estimated date 
of HIV infection resulted in a set of 32 cases collected at a median of 14 days after infection 
(IQR 14 days after to 17 days before infection, 20/32 [65.6%] were after infection).
Levels of exogenous hormones.
From samples drawn at the visit with the first evidence of infection, MPA alone was detected 
in 29.5% of cases and 22.7% of controls and most frequently in low amounts (0.02-0.50 
ng/ml) (Table 2). When detected, the median quantity of MPA was 0.41 (IQR 0.15-1.03) 
overall. LNG alone was detected in 11.8% of cases (n=10 samples) and 8.7% of controls 
(n=35 samples) with a median quantity of 0.86 ng/ml (IQR 0.33-2.56) when detected. NET 
alone was detected in 2.6% of cases (n=2 samples) and 3.2% of controls (n=12 samples) 
with a median quantity of 0.83 ng/ml, (IQR 0.23-2.42) when detected. ENG alone was 
detected in 2.6% of cases (n=2 samples) and 3.2% of controls (n=12 samples), with a 
median of 0.25 ng/ml, (IQR 0.18-0.36) when detected. Using the set of cases and controls 
drawn from the visit immediately prior to the visit with first evidence of infection, 
distributions and frequencies of progestin detection were very similar.
Association between exogenous hormone in serum and HIV.
The frequency of MPA detection was not significantly different between cases and controls, 
both for samples from the visit with the first evidence of infection (adjusted OR=1.31, 95% 
CI 0.81-2.14) and samples from the visit prior to the first evidence of infection (adjusted OR 
= 1.33, 95% CI 0.79-2.23, Table 3). However, when cases were restricted to those with a 
sample tested within 30 days of estimated HIV infection and further to those with a sample 
within 15 days of HIV infection, there was an association of MPA detection and HIV risk 
with point estimates of 1.75 (95% CI 0.97-3.14) and 2.75 (95% CI 1.22-6.19), respectively. 
With regards to MPA quantity, there was no indication of a dose-response pattern between 
increasing MPA levels and odds of HIV acquisition. Only the lowest levels of detectable 
MPA (0.02-0.50 ng/ml relative to no detectable MPA) were associated with elevated HIV 
risk: adjusted OR=1.67, 95% CI 0.94-2.98 among case samples collected from the first 
evidence of infection; adjusted OR=2.16, 95% CI 1.17-3.99 among case samples collected 
from the visit prior to the first evidence of infection; adjusted OR=3.24, 95% CI 1.63-6.46 
for cases within 30 days of HIV infection; adjusted OR=6.03, 95% CI 2.50-14.54 for cases 
within 15 days of HIV infection. Adding E2 to the models did not change the results 
substantially. No other progestin was associated with HIV risk.
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Discussion
In this case-control study, we found some evidence that seroconverting women were more 
likely to have MPA detected than a matched set of non-seroconverting women. The 
association was statistically significant when we limited our analysis to samples drawn 
closest to the estimated day of HIV infection. Notably, only low serum levels of MPA 
(0.02-0.50 ng/ml), but not higher levels, were associated with increased risk of HIV relative 
to samples with MPA undetected. Recent work, including from the cohorts in this study and 
others, has demonstrated that self-reported data on hormonal contraceptive use may 
inaccurately reflect serum levels of exogenous hormones, with up to 30% of women having 
exogenous hormones detected while reporting no hormonal contraceptive use (9, 24, 28). By 
using serum MPA levels, this study provides objective evidence relating MPA to HIV risk 
beyond that of prior studies that have relied on self-reported contraceptive use data.
Our findings are somewhat contrary to hypotheses about possible mechanisms by which 
DMPA could increase HIV vulnerability. Pharmacokinetic studies have demonstrated that 
injectable contraceptives have high serum levels following injection that taper off until levels 
fall below the threshold for contraceptive efficacy and subsequent injection is required. 
Hypotheses about HIV risk have suggested that risk may be greatest when levels of MPA are 
highest and could potentially wane as MPA levels reduce (12, 29, 30). Our data could be 
interpreted as suggesting that small levels of MPA in serum could increase risk. The 
association between low MPA levels and HIV risk may support hypotheses about DMPA 
and HIV susceptibility that are based on the high glucocorticoid binding affinity of MPA, 
which is unique to MPA as a synthetic progestin and may not be dose dependent (31). In in 
vitro studies, MPA can stimulate and inhibit transcription of target genes observed through 
changes in cytokines and chemokines, suggesting that a high dose may not be required to 
elicit mechanisms that increase HIV vulnerability (12). However, further research is needed 
to explore these hypotheses in order to better understand the potential clinical and/or 
programmatic implications of these findings.
A lower dose subcutaneously-administered form of DMPA (DMPA-SC) available in a self-
injection device has been demonstrated to have higher continuation rates than the standard 
intramuscularly injected DMPA (32, 33). Relative to intramuscular DMPA, it has been 
postulated that the lower dose (104 mg in DMPA-SC relative to the 150 mg delivered 
through intramuscular DMPA) could result in lower maximum concentration (Cmax) values 
of MPA and differential effects on biologic mechanisms that might enhance susceptibility to 
HIV during the first 30 days after administration (34). While our results have limitations, 
they would suggest that a lower MPA Cmax may not be the most important feature to 
overcome in efforts to decrease HIV risk and support the need for head-to-head comparison 
studies of MPA formulations to determine whether HIV risk is different based on the route 
of administration or amount of MPA delivered (34).
Current epidemiologic data do not raise concerns about the impact of oral contraceptives on 
HIV risk and little is known about HIV risk with other contraceptive methods, including 
NET-EN and hormonal implants that contain LNG or ENG (6). It is reassuring that we do 
not see any trend for other progestins (LNG, NET, or ENG) to be more frequently detected 
Heffron et al. Page 8
AIDS. Author manuscript; available in PMC 2020 March 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
in seroconverting versus non-seroconverting women. However, our ability to draw 
conclusions about these hormones is limited by the infrequent use of contraceptive methods 
containing these progestins in sub-Saharan Africa.
This is a unique study of serum MPA levels drawn from a large cohort of women and we 
carefully considered ways to account for misclassification in our analysis. Nonetheless, the 
study has limitations. Our selected case samples were a mix of those collected before and 
after the estimated date of HIV infection and we lacked data on the dates when DMPA 
injections were administered. Given the early marked peak and subsequent decline of serum 
MPA levels following DMPA injection, serum MPA measured in samples collected on the 
day with the first evidence of infection are likely different from the level on the day when 
HIV infection actually occurred. Our analyses restricting case samples to those closest to the 
estimated date of infection help to focus on data with potentially fewer misclassifications but 
these subsets contain small numbers of cases and samples were drawn after the estimated 
date of infection on average, raising the possibility for serum levels on the date of infection 
to have been greater than we measured. We lacked samples with MPA levels that are near 
the expected Cmax levels and the infrequent sampling scheme for these clinical trials does 
not allow us to evaluate peak MPA levels or cumulative MPA exposure among cases 
compared with controls. Thus, our results should be used to generate new hypotheses about 
mechanisms related to DMPA and HIV susceptibility that can be explored in well-powered 
clinical studies and incorporate laboratory measurement of MPA levels that are sampled at a 
range of times following injection.
DMPA is the most widely used contraceptive in East and southern Africa, where over half 
the burden of HIV is carried by heterosexual women (3). Understanding mechanisms by 
which intramuscular DMPA may potentially increase HIV susceptibility, including 
biological and behavioral mechanisms and with varying quantities of MPA, is a priority for 
women’s health and is needed to drive development of novel methods that will not increase 
HIV vulnerability. WHO closely monitors the development of novel data pertaining to the 
question of hormonal contraception and HIV risk and continues to call for higher quality 
data to permit more definitive conclusions and recommendations. Incorporating quantitative 
measurements of hormonal exposure into contraceptive studies will lead to better accuracy 
in exposure measurement and permit disaggregation into low, medium, and high hormonal 
levels to look for dose-response trends. These efforts will further our understanding of 
current contraceptive methods and can be integrated into efforts to develop novel methods 
and expansion of the contraceptive method mix.
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Figure 1. 
Selection criteria for cases and controls
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